Fidelity Investments
IMMX icon

Fidelity Investments’s Immix Biopharma IMMX Stock Holding History

Fidelity Investments’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7
Closed -$16 – 5405
2022
Q4 		$16 Sell
7
-2
-22% -$3 ﹤0.01% 5167
2022
Q3 		$0 Buy
+9
New +$20 ﹤0.01% 5153

Other funds holding IMMX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UB
UMB Bank Kansas City, Missouri $7.16B AUM 20.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
ICG
InterOcean Capital Group Nashville, Tennessee $4.19B AUM 26.29% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments's IMMX Position: Q1 2023 in Review

Fidelity Investments sold out of Immix Biopharma (IMMX) in Q1 2023, closing a stake of 7 shares — an estimated $16 sold.

Fidelity Investments first reported a position in IMMX in Q3 2022 and held it in 2 quarters. The position peaked at $16 in Q4 2022. 12 funds tracked by Wall St. Rank hold IMMX as of Q1 2023.

  • Fidelity Investments reported no remaining Immix Biopharma position as of Q1 2023 after selling out during the quarter.
  • Fidelity Investments sold 7 Immix Biopharma shares in Q1 2023, an estimated $16.
  • Fidelity Investments first reported a position in Immix Biopharma in Q3 2022 and held it in 2 quarters.
  • Fidelity Investments's Immix Biopharma position peaked at $16 in Q4 2022.
  • 12 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2023.

Based on Fidelity Investments's 13F filing for Q1 2023, filed 11 May 2023.